News

26.12.2018

Tracon Pharmaceuticals Presents Positive Top-line Clinical Data from Dose Escalation Portion of Phase 1 Trial of TRC105 and Opdivo® for Treatment of Non-Small Cell Lung Cancer

21.12.2018

Tracon Pharmaceuticals Announces Top-line Data from Phase 2 TRAXAR Clinical Trial in Renal Cell Carcinoma

07.12.2018

Arvinas Presents Preclinical Data on Protein Degrader, ARV-471, at the 2018 San Antonio Breast Cancer Symposium (SABCS)

06.12.2018

Neon Therapeutics and Apexigen Announce First Patient Dosed in Neon’s NT-003 Phase 1b Combination Trial of NEO-PV-01 in Metastatic Melanoma

Blueprint Medicines Announces Updated Results from Ongoing EXPLORER Clinical Trial of Avapritinib Demonstrating Broad Clinical Activity and Significant Symptom Reductions in Patients with Systemic Mastocytosis

02.12.2018

Kura Oncology Announces Proof of Concept in Angioimmunoblastic T-Cell Lymphoma, Validation of CXCL12 as a Therapeutic Target of Tipifarnib in Peripheral T-Cell Lymphoma

02.12.2018

Autolus Therapeutics Presents Initial AUTO3 Clinical Data from Phase 1/2 Clinical Trials in B cell Malignancies at the 60th ASH Annual Meeting

01.12.2018

Autolus Therapeutics Announces Update on its Novel CAR T Cell Program for Peripheral T Cell Lymphoma (PTCL)

29.11.2018

TRACON Pharmaceuticals and I-Mab Biopharma Announce Strategic Partnerships for Multiple Immuno-Oncology Programs

28.11.2018

Kura Oncology announces New Patent for Tipifarnib in Angioimmunoblastic T-Cell Lymphoma

15.11.2018

Blueprint Medicines Announces Updated NAVIGATOR Trial Results in Patients with Advanced Gastrointestinal Stromal Tumors Supporting Development of Avapritinib Across All Lines of Therapy

09.11.2018

Neon Therapeutics presents Updated Data at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting

08.11.2018

Neon Therapeutics appoints Industry Veteran Robert Bazemore to its Board of Directors

08.11.2018

Kura Oncology adds Commercial Veteran Mary Szela to Board of Directors

01.11.2018

Kura Oncology Announces Upcoming Presentations at ASH Annual Meeting

23.10.2018

IDEAYA Biosciences has entered into an exclusive license agreement with Novartis

22.10.2018

Kura Oncology presents Update on Positive Phase 2 Trial of Tipifarnib in HRAS Mutant HNSCC and Preliminary Results in HRAS Mutant SCC

16.10.2018

Revolution Medicines Acquires Warp Drive Bio to Expand Drug Discovery Portfolio Focused on Frontier Oncology Targets

09.10.2018

Revolution Medicines announces First Patient Dosed with RMC-4630 in Phase 1 Clinical Study in Patients with Advanced Solid Tumors

06.10.2018

Blueprint Medicines announces Updated Data from Phase 1 ARROW Clinical Trial Showing Broad, Durable Activity of BLU-667 in Advanced RET-Altered Medullary and Papillary Thyroid Cancers

Events

Past Events

07.01. – 10.01.2019

J.P. Morgan 37th Annual Healthcare Conference
San Francisco, CA, USA

13.11. – 16.11.2018

30th EORTC-NCI-AACR SYMPOSIUM
Dublin, Ireland

12.11. – 16.11.2018

PEGS Europe
Lisbon, Portugal

19.10. – 23.10.2018

ESMO 2018 Congress
Munich, Germany

10.10.2018

The UK biopharma research & development Summit
London, UK

Keep me updated about investment opportunities in the area of oncology and life sciences.

Latest Newsletters

January 2019 June 2018 April 2018

Sitemap Sitemap

Nextech Invest Ltd.Turnerstrasse 26, 8006 Zurich, Switzerland P +41 (0)44 366 66 11 F +41 (0)44 366 66 10Privacy Policy

Newsletter Registration

Please fill in the subscription form completely. If you wish to modify your personal data or to change/cancel your newsletter subscription, this is possible at any time.

A link to your subscription profile can be found in every newsletter email.

* Compulsory fields

Newsletter Registration

Your eMail have been successfully registered.

This website uses cookies to provide you with the best possible service. By using our website, you consent to the use of cookies in accordance with our privacy policy. Here you can find out more.